Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Pharmacol. 2013 Sep 1;86(5):691-702. doi: 10.1016/j.bcp.2013.06.029. Epub 2013 Jul 12.

Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.

Author information

1
DMPK, AstraZeneca R&D Mölndal, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. maria.ulvestad@farmasi.uio.no

Abstract

Human embryonic and induced pluripotent stem cell-derived hepatocytes (hESC-Hep and hiPSC-Hep) have the potential to provide relevant human in vitro model systems for toxicity testing and drug discovery studies. In this study, the expression and function of important drug metabolizing cytochrome P450 (CYP) enzymes and transporter proteins in hESC-Hep and hiPSC-Hep were compared to cryopreserved human primary hepatocytes (hphep) and HepG2 cells. Overall, CYP activities in hESC-Hep and hiPSC-Hep were much lower than in hphep cultured for 4 h, but CYP1A and 3A activities were comparable to levels in hphep cultured for 48h (CYP1A: 35% and 26% of 48 h hphep, respectively; CYP3A: 80% and 440% of 48 h hphep, respectively). Importantly, in hESC-Hep and hiPSC-Hep, CYP activities were stable or increasing for at least one week in culture which was in contrast to the rapid loss of CYP activities in cultured hphep between 4 and 48 h after plating. With regard to transporters, in hESC-Hep and hiPSC-Hep, pronounced NTCP activity (17% and 29% of 4 h hphep, respectively) and moderate BSEP activity (6% and 8% of 4 h hphep, respectively) were observed. Analyses of mRNA expression and immunocytochemistry supported the observed CYP and transporter activities and showed expression of additional CYPs and transporters. In conclusion, the stable expression and function of CYPs and transporters in hESC-Hep and hiPSC-Hep for at least one week opens up the possibility to reproducibly perform long term and extensive studies, e.g. chronic toxicity testing, in a stem cell-derived hepatic system.

KEYWORDS:

BCRP; BSEP; BSP; CYP; Cytochrome P450; E17βG; E3S; Hepatocytes; Human embryonic stem cell-derived hepatocytes; Human induced pluripotent stem cell-derived hepatocytes; MDR1; MRP2; NTCP; OATP1B1; OCT1; RIT; TCA; Transporter proteins; bile salt export pump; breast cancer resistance protein; bromosulfophtalein; cytochrome P450; day 29 or 36; estradiol-17β-d-glucuronide; estrone-3-sulfate; hESC; hESC-Hep; hepatocyte cultures 29 or 36 days respectively after start of the hepatic differentiation protocol; hiPSC; hiPSC-Hep; hphep; human embryonic stem cell-derived hepatocytes; human embryonic stem cells; human induced pluripotent stem cell-derived hepatocytes; human induced pluripotent stem cells; human primary hepatocytes; multidrug resistance protein 1; multidrug resistance protein 2; organic anion-transporting polypeptide 1B1; organic cation transporter 1; ritonavir; sodium-taurocholate cotransporting polypeptide; taurocholic acid

PMID:
23856292
DOI:
10.1016/j.bcp.2013.06.029
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center